Structural Heart

This structural heart channel includes news, videos, podcasts and other content related to diagnosis and treatment of structural heart disease. Topics covered include heart valve repair and replacement, transcatheter aortic valve replacement (TAVR), transcatheter mitral valve replacement (TMVR), transcatheter tricuspid valve replacement (TTVR), left atrial appendage (LAA) occlusion, heart failure interventional device therapies, and closing holes in the heart using, including occlusion of atrial septal defects (ASDs), ventricular septal defects (VSDs) and patent foramen ovales (PFOs).

Videos | Structural Heart | April 01, 2020

A review of the PARTNER 3 Low-Risk Trial with ...

The Edwards Lifesciences Cardioband for tricuspid valve regurgitation. #COVID19 #coronavirus

The Edwards Lifesciences Cardioband for tricuspid valve regurgitation is one of the device trials being paused for the duration of the COVID-19 outbreak.

News | Heart Valve Technology | March 30, 2020

March 30, 2020 — Edwards Lifesciences Corp. announced it is temporarily pausing new enrollments in its active...

Conclusions from the TAVR vs surgery trial for aortic valve replacement in the U.K. presented by William D. Toff, M.D. at ACC 20. #ACC20 #ACC2020 #TAVR #TAVR

Conclusions from the real world TAVR vs. surgery trial for aortic valve replacement outcomes in the U.K., presented by William D. Toff, M.D. at ACC 20. 

News | Heart Valve Technology | March 30, 2020

March 30, 2020 — Patients in the United Kingdom (U.K.) who underwent transcatheter aortic valve replacement (TAVR)...

PARTNER 3 trial shows positive results for Sapien 3 in low-risk surgical patients. #ACC20 #ACC2020 #Sapien3 #TAVR
Feature | Heart Valve Technology | March 30, 2020

March 30, 2020 — Patients undergoing transcatheter aortic valve repair (TAVR) low-risk patients at two years did...

News | Heart Valve Technology | March 29, 2020

March 29, 2020 — Worse than expected outcomes were found for survival and quality of life among patients undergoing...

Patients with bicuspid, or two-leaflet, aortic valves who undergo transcatheter aortic valve replacement (TAVR) procedures had a high rate of success and low risk of death or disabling stroke at 30 days, according to new data presented at the American College of Cardiology (ACC) 2020 Scientific Session. #ACC20 #ACC2020
Feature | Heart Valve Technology | March 29, 2020 | Dave Fornell, Editor

March 29, 2020 — Patients with bicuspid, or two-leaflet, aortic valves who undergo transcatheter aortic valve...

POPULAR TAVR trial Shows Oral Anticoagulants Alone in atrial fibrillation  (AF) Patients Reduces Bleeding Post TAVR, transcatheter aortic valve replacement. #ACC20 #ACC2020
News | Atrial Fibrillation | March 29, 2020

March 29, 2020 — Patients with atrial fibrillation (AF) who took oral anticoagulants alone after undergoing...

The heart team at St. James University Hospital Dublin was the first to perform a human implant of the CroiValve Duo Tricuspid Coaptation Valve technology for tricuspid repair.  

The heart team at St. James University Hospital Dublin was the first to perform a human implant of the CroiValve Duo Tricuspid Coaptation Valve technology for tricuspid repair.  

News | Heart Valve Technology | March 25, 2020

 

March 25, 2020 — CroiValve announced the successful first human use of its Duo Tricuspid Coaptation Valve...

A 3-D reconstruction of a cardiac CT scan showing an implanted Medtronic CoreValve TAVR device. Imagine courtesy of TeraRecon. #TAVR #TAVI

A 3-D reconstruction of a cardiac CT scan showing an implanted Medtronic CoreValve TAVR device. Image courtesy of TeraRecon

Feature | Heart Valve Technology | February 24, 2020 | Dave Fornell, Editor

In August 2019, the U.S. Food and Drug Administration (FDA) expanded the indication for the use of transcatheter...

The American College of Cardiology (ACC) released a list of the latest practice-changing presentations at the ACC.20 annual meeting March 28-30, 2020, in Chicago. This includes five late-breaking clinical trial (LBCT) sessions and three featured clinical research sessions. There also are two LBCT deep-dive sessions where the experts will break down the hottest trials and attendees can find out what the impact might be on the practice of cardiology and patients.
Feature | ACC | March 27, 2020 | Dave Fornell, Editor

Here is the list of American College of Cardiology (ACC) practice...

The U.S. Food and Drug Administration (FDA) has approved a the CATALYST trial designed to assess Abbott's Amplatzer Amulet left atrial appendage (LAA) occluder for people with atrial fibrillation (AF or AFib). 
News | Left Atrial Appendage (LAA) Occluders | February 03, 2020

February 3, 2020 — The U.S. Food and Drug Administration (FDA) has approved a the...

The Abbott Tendyne transcatheter mitral valve replacement (TMVR) system, left, became the first TMVR device to gain commercial regulatory clearance in the world. It gains European CE mark in January. Another top story in January was the first use of the Robocath R-One robotic cath lab catheter guidance system in Germany.  Watch a VIDEO of the system in use in one of those cases. 

The Abbott Tendyne transcatheter mitral valve replacement (TMVR) system, left, became the first TMVR device to gain commercial regulatory clearance in the world. It gains European CE mark in January. Another top story in January was the first use of the Robocath R-One robotic cath lab catheter guidance system in Germany.  Watch a VIDEO of the system in use in one of those cases. 

News | February 03, 2020 | Dave Fornell, Editor

February 3, 2020 — Here is the list of the most popular content on the Diagnostic and Interventional Cardiology (...

Overlay Init